TABLE 1.
Demographics of the Hotgen clinical evaluation cohorts for Brazil and the United Kingdom
| Characteristica | Brazil (total), n = 446 | Brazil reference center, n = 309 | Brazil community center, n = 137 | UK community drive-through, n = 246 |
|---|---|---|---|---|
| Age, yr [median (min–max), N] | 36.0 (18–81), 446 | 35.0 (19–80), 309 | 41.0 (18–81), 137 | 40.6 (18–76), 246 |
| Gender [% F (n/N)] | 59.9% (267/446) | 59.9% (185/309) | 59.9% (82/137) | 57.1% (140/246) |
| Days from symptom onset [median (Q1–Q3); N] | 3 (3–5), 445 | 3 (2–4), 309 | 4 (3–6), 136 | 2 (2–3), 246 |
| Days <0–3 (n, %) | 233, 52.4% | 170, 55.0% | 63, 46.3% | 221, 89.51% |
| Days 4–7 (n, %) | 195, 43.8% | 134, 43.4% | 61, 44.9% | 25, 10.13% |
| Days 8+ (n, %) | 17, 3.8% | 5, 1.6% | 12, 8.8% | 13, 0.45% |
| Vaccinated (n, %) | 154, 34.5% | 126, 40.8% | 28, 20.4% | 194, 78.9% |
| Not vaccinated (n, %) | 292, 65.5% | 183, 59.2% | 109, 79.6% | 51, 20.7% |
| Vaccination not disclosed (n, %) | 0 | 0 | 0 | 1, 0.4% |
| RT-qPCR positivity (%, n/N) | 24.0% (107/446) | 19.4% (60/309) | 34.3% (47/137) | 27.2% (67/246) |
a
min, minimum; max, maximum; F, female; n, number with characteristic; N, total number.